Cohance Lifesciences

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA by India Ratings.
• ResultsLoss-makingLost ₹45 Cr in the Jun 2026 quarter, after a profit a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersPromoters sellingThe promoters (founders or parent) own 57%, down from 66% in Jun 2025.
• ValuationExpensive vs its pastThe share trades at 169.2 times its yearly earnings (P/E), pricier than 100% of the time in the last 5 years. Its usual P/E is about 38.

Cohance Lifesciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)169.2 against a typical 34.3: pricier than most peers (1st = cheapest).205th of 220
• Sales growth−23.1% against a typical +15.6% from a year earlier.177th of 197
• Profit growth−197.8% against a typical +18.9% from a year earlier.154th of 160
• Share price, 3 months+9.6% against a typical −0.5%.63rd of 200
• Size₹ 17,304.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).26th of 199

Exchange filings and their impact on the company.

• 12 Oct 2026General UpdatesLow impactPositivePrice −1.6% on 13 Oct
  Government approved Umang Vohra's continuation as Chairman and Group CEO, securing leadership stability.

  Cohance Lifesciences said the Ministry of Corporate Affairs approved the appointment of Umang Vohra as Chairman and Group CEO, via a letter dated 8 October 2026 received on 12 October 2026. The appointment was originally announced in April and June 2026. The approval secures leadership continuity under the former Cipla chief, which should support stable execution over the next year.

  Full analysisFiling
• 9 Oct 2026General UpdatesLow impactNeutralPrice +0.8% on 12 Oct
  Granted 8.7 lakh stock options (~0.23% dilution) with no vesting for a year, so near-term financial impact is negligible.

  Cohance Lifesciences granted 8,74,788 stock options on 9 Oct 2026 - 2,60,194 under ESOP 2026 at Rs 325 exercise price and 6,14,594 under ESOP 2023 at Rs 495. Each option converts to one Rs 1 share, vesting after 1 year and exercisable within 3 years of vesting. With dilution of only ~0.23% and no vesting in the next year, the near-term earnings impact is limited to a small annual ESOP charge.

  Full analysisFiling
• 9 Oct 2026AppointmentLow impactNeutralPrice +0.8% on 12 Oct
  Cohance named experienced pharma finance leader Abhimanyu Ojha as CFO from 12 October 2026.

  Cohance Lifesciences said its board on 9 October 2026 approved the appointment of Abhimanyu Ojha as Chief Financial Officer and Key Managerial Personnel effective 12 October 2026. Ojha has over two decades in pharma finance, most recently as Global CFO at Intas Pharmaceuticals, with earlier roles at Viatris, Sun Pharma and Ranbaxy. The change ensures leadership continuity but carries no immediate financial impact.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Vivek Sharma

Executive Chairman of the Board

Yann D'herve

Chief Executive Officer

Himanshu Agarwal

Chief Financial Officer, Whole-Time Director

Sisir Kumar Mishra

Compliance Officer, Company Secretary